A clinical study of MVR-T3011 IT in combination of Cobimetinib to evaluate the safety and efficacy of this combo strategy
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Cobimetinib (Primary) ; T 3011 (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 22 Apr 2022 New trial record
- 19 Apr 2022 According to an Immvira Pharma media release, the company has collaborated with the Roche to conduct clinical studies in the USA.